Jim Cramer Says Pfizer "Will Continue to Sell at Eight Times Earnings"

Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School students. A student asked if the stock, given the company’s reputation for innovation, its decline of over 50% from its peak, and recent deals involving Metsera and the Trump administration on drug pricing, is now a buy. In response, Cramer said:

“No. Pfizer sells at eight times earnings and will continue to sell at eight times earnings. I’ll give you an example of what Dr. Bourla should have done. He should have done a preemptive bid and get that. He really needs, he needs to go up again slowly. He does not have a growth engine. We’re beginning to believe that Seagen, which is the old Seattle Genetics acquisition, has not produced the results that we thought. He had an upside surprise in both earnings and revenues, and the stock did not go up. That is what I call an uninvestible situation.”

Pfizer Inc. (NYSE:PFE) develops and sells medicines and vaccines across therapeutic areas, including cardiovascular, infectious diseases, immunology, and oncology.

While we acknowledge the potential of SBUX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.